Market expectations are rising for Hugel following its announcement of results that far exceeded projections. Analysts predict that the company's strong performance will continue in the second half of…

There is a prediction in the securities industry that GC, which showed poor performance in Q2 this year, will succeed in turning the atmosphere around in the second half. It is expected that sales of…

Celltrion's 'Zymfentra', has been successfully listed in the formularies of all three major Pharmacy Benefit Managers (or PBMs) in the United States. On August 5, Celltrion announced on its website…

The obesity treatment drug 'Mounjaro' (active ingredient: tirzepatide), which has shown powerful weight loss effects exceeding 20%, has been approved in South Korea. This medication, gaining…

Samsung, which ambitiously announced its expansion into the healthcare sector, is now facing a significant problem with the rapid battery drain of its smartwatches. This issue follows recent criticism…

Hanmi Pharmaceutical has achieved robust performance due to strong sales of key products and the growth of its subsidiaries. The company announced on the 30th that it recorded consolidated sales of…

Daewoong Pharmaceutical announced on the 29th that its new drug 'Bersiporocin', currently being developed as the world's first treatment for idiopathic pulmonary fibrosis (IPF), has proven its safety…

ST Pharm, which recorded a deficit in the first half of the year, is expected to see a rebound in performance in the second half. On the 26th, the securities industry projected that ST Pharm's…

“60,000 Celltrion shareholders firmly oppose the merger with Celltrion Pharm, which undermines shareholder value. We strongly urge the company to swiftly announce a clear and detailed stance on the…

GC Biopharma Corp's new immune globulin drug 'Alyglo' is set to enter the U.S. market after 8 years of efforts. According to the pharmaceutical industry on the 25th, GC Biopharma plans to officially…